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ABSTRACT  The  cellular  mechanisms  of degradation  of a transmembrane  protein, the acetyl- 
choline receptor (AChR),  have been examined in a mouse  muscle  cell  line, BC3H-1. The half- 
time of degradation of cell  surface  receptors  labeled  with [1251]a-Bungarotoxin  ([1251]a-BuTx) 
is 11-16 h. Leupeptin, a Iysosomal protease inhibitor, slows the degradation rate two- to sixfold, 
depending on the concentration of inhibitor used. The inhibition is reversible  since the normal 
degradation  rate  is regained  within 20 h after removal  of the inhibitor. Cells  incubated  with 
leupeptin  accumulate  AChR.  Little change  in  the  number  of  surface  AChR  occurs  but  the 
amount of intracellular  AChR increases two- to threefold.  Accumulated  AChR  are  unable  to 
bind [~251]a-BuTx if excess, unlabeled ~-BuTx is present in the culture medium during leupeptin 
treatment. Thus,  leupeptin causes the accumulation  of a surface-derived  receptor population 
not previously described  in these cells.  Subcellular fractionation studies utilizing Percoll  and 
metrizamide  gradient centrifugation  in addition to molecular  exclusion chromatography  sug- 
gest  that the accumulated  AChR  reside  in  a compartment  with  Iysosomal  characteristics.  In 
contrast, the subcellular component containing another intracellular pool of AChR not derived 
from  the surface  is clearly separated  from  lysosomes on  Percoll  gradients. The sedimentation 
properties of AChR  solubilized  from  the plasma  membrane  and the lysosomal  fraction  have 
been  compared.  The  plasma  membrane  AChR  exhibits a sedimentation  coefficient of 9S  in 
sucrose  gradients containing Triton, whereas the AChR derived  from  the  lysosomal  fraction 
exists in part in a high molecular weight form. The large aggregate and the organelle in which 
it resides may represent  important intermediates in the degradative pathway of this membrane 
protein. 
Large changes occur in the amount, metabolic stability, and 
distribution of the AChR during the maturation process of the 
neuromuscular junction  as well as after muscle denervation 
(for  reviews,  see  references  26,  31,  56,  15).  Some  of these 
changes involve alterations in the rates of synthesis, degrada- 
tion, and incorporation of the receptor into the surface mem- 
brane. The biochemical nature of both synthesis (2, 19, 20, 30, 
35, 53, 54) and degradation (12, 22, 23, 25, 27, 46, 47, 57, 59) 
has been the focus of numerous studies. 
In addition to their possible involvement in synaptogenesis, 
changes in the degradation rate of AChR may play an impor- 
tant role in the cause of the neuromuscular disease, myasthenia 
gravis. Sera from patients with this disease contain antibodies 
to the AChR (48), and the interaction of antibodies with the 
receptor is thought  to  be  at  least partly responsible for the 
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pathogenesis of the disease (for reviews, see references 29, 49, 
50).  Antibodies to AChR induce an abnormally rapid rate of 
turnover of the AChR in muscle (5,  14, 35,  37,  43,  55).  The 
subsequent decrease in the synaptic content of AChR contrib- 
utes to the failure of synaptic transmission at affected muscles. 
Much of the information concerning the cellular degradation 
pathway of AChR is based on morphological studies. A more 
detailed understanding of the biochemical mechanisms of deg- 
radation could be beneficial to efforts in developing treatments 
for myasthenia gravis. 
A  study of the cellular mechanism of AChR turnover is of 
interest in  a  more  general sense  as a  model system  for  the 
degradation of transmembrane proteins. The metabolic fate of 
cell surface membrane  receptors and  their ligands has  been 
studied  in  a  variety of experimental systems  including  the 
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32, 36, 41, 42,  58),  the low density lipoprotein receptor (3, 4, 
21),  and  polypeptide  hormone  receptors  (9,  38).  Antibody- 
induced  internalization  has been  used as a  tool to study the 
degradation of cell surface membrane constituents as well (11, 
39). For several reasons, the AChR may provide an ideal model 
system for the study of the turnover of membrane proteins. Its 
normal degradative process is not induced by ligand binding, 
nor is antibody induction of its turnover necessary to facilitate 
biochemical  analysis.  The availability  of [12sI]a-BuTx,  a high 
affmity specific ligand for the receptor, provides an extremely 
convenient means for its detection throughout the degradative 
pathway and thus facilitates  analysis of the turnover process. 
Finally,  the AChR is rapidly becoming one of the most thor- 
oughly characterized of all multisubunit transmembrane pro- 
teins.  This  information  will  eventually  be very useful  in ex- 
amining the  biochemical  properties responsible  for the regu- 
lation of degradative rates. 
The focus of this study is a biochemical analysis of the steps 
involved  in  the  degradation  pathway  of  the  AChR  in  the 
mouse cell  line,  BC3H-I.  Four approaches were utilized  for 
this purpose:  (a) measurement of the degradation rate of the 
AChR  and  the  effects  of blocking  the  degradation  with  the 
protease  inhibitor  leupeptin;  (b)  quantitation  of the  distinct 
receptor pools present in these cells and determination of the 
effect  of  leupeptin  treatment  on  pool  sizes;  (c)  subcellular 
fractionation  to  identify  the  cellular  organelles  involved  in 
degradation; and (d) biochemical characterization of internal- 
ized toxin-receptor complexes. The experiments detailed below 
demonstrate that leupeptin treatment inhibits the degradation 
of AChR and causes accumulation of a population of receptors 
derived from the cell surface  which  has not been previously 
described  in  these  cells.  This  leupeptin-augmented  receptor 
appears to reside in a lysosomal compartment and exists in at 
least two forms differing in sedimentation properties. A prelim- 
inary report of this work has appeared (40). 
MATERIALS  AND  METHODS 
Materials:  Sephacryl S-1000, Percoll, and the density bead marker kit 
were purchased from Pharmacia Fine Chemicals, Plscataway, NJ. Metrizamide 
and maxidens oil were obtained from Nyegaard, distributed through Accurate 
Chemical & Scientific Corp., Westbury, NY. Leupeptin was kindly provided by 
Dr. Alfred Stracher, Department of Biochemistry, Down State Medical Center, 
Brooklyn, NY, or was purchased from the Peptide Institute, Minoh-Shi, Osaka, 
Japan. Fetal cuff serum (FCS) was obtained from M. A. Bioproducts, Walkers- 
ville, MD. Na~261 was obtained from Amersham Corp., Arlington Heights, IL. A 
17-ml zero clearance homogenizer was purchased from Kontes Co., Vineland, 
NJ. All other reagents were obtained from Sigma Chemical Co., St. Louis, MO. 
[~2sI]a-BuTx was prepared as previously described (33). 
Tissue Culture:  BC3H-1 cells were cultured as described by Patrick et 
al. (57). Ceils were passaged every 4 d in order to maintain logarithmic phase of 
growth. Cells were plated at 2 x  10a/cm  2 on 60-ram plastic tissue culture dishes. 
For turnover studies, cells were allowed to enter stationary phase growth and 
were used within 10 d of passage. 
Enzyme Assays:  N-Acetyl-fl-glucosammidase  (NAflGase) was assayed 
using the methylumbelliferyl-derivatized substrate according to the method of 
Barrett (10) with slight modifications. The t-real incubation mixture contained 4- 
methyhimbelliferyl N-acetyl-fl-D-ghicosaminidine (0.5 raM), sucrose (0.25 M), 
Triton X-100 (0.33%), 0.1  M sodium citrate, pH 5.0, and bovine serum albumin 
(BSA) (0.17 mg/ml). The reaction was initiated by the addition of enzyme and 
terminated by the addition of bicarbonate-carbonate stop solution after incuba- 
tion for 9 mm at 37°C. Reaction product was detected fluorometricaUy with an 
excitation beam of 375 am and emission measured at 460 nm. To construct a 
standard curve, 0.25 ml of methylumbelliferone solutions in the concentration 
range of 0.0025-0.025 mM  were included in reaction mixtures instead of the 
enzyme. Protein was determined according to the method of Bradford (17) with 
manor modifications. Samples ( 100/.il) containing 0.15-2.5 ng protein were mixed 
with 0.5 ml of the protein reagent and the As~ was determined. BSA standards 
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were  used to  generate a  standard curve. To  measure the  protein  content  of 
samples that contained Percoll, aliquots were made 0.5% in SDS and incubated 
at 25°C for 1 h. The samples were then centrifuged in a  Beckman LP42 rotor 
(Beckman Instruments, Inc., Fullerton, CA) at 28,500 rpm for 1 h  to pellet the 
Percoll.  Samples  (20 #1)  of the  supernatants were  analyzed as  described  by 
Bramhall et al. (18). 
AChR  Turnover  Experiments:  Procedures  similar  to  those  de- 
scribed by Patrick et al. (57) were used. To label surface AChR of BC3H-I cells, 
cultures were incubated in Dulbecco's Modified Eagle's Medium (DME), 0.2% 
FCS (0.2% DME) containing 1 x  10  -a M [~2aI]a-BuTx for one h at 37°C, washed 
to  remove  unbound  toxin,  and placed  in  growth medium.  At  various  time 
intervals, duplicate aliquots of culture medium were removed and replaced with 
fresh medium. Radioactivity in the aliquots was determined in a  gamma 4000 
counter (Beckman Instruments Inc.). At the end of the incubation period, the 
cultures were washed two times with 2  ml of 138 mM NaCI, 3  mM KC1, 8.15 
mM  Na2HPO4,  1.47  mM  KH2PO4 (NaCI/PI)  and the ceils were collected by 
centrifugation in a microfuge (Beckman Instruments Inc.). Cell pellets were then 
counted. The radioactivity  associated with ceils at the beginning of  the experiment 
was calculated by summing that found in the cell pellet with that in the medium. 
Chromatography of an aliquot of the medium on a Bin-Gel P-2 column verified 
that the radioactivity excreted by the cells had the properties of [~ZSl]tyrosine (13) 
(data  not  shown).  Degradation half-times  of toxin-receptor complexes  were 
determined  by plotting the  percentage of radioactivity which  remained cell- 
associated on a semilog scale against time of incubation. The rate of [~2~l]a-BuTx 
dissociation from the receptors is slow compared with the rate of degradation 
(59). 
Quantitation of AChR Pools:  BC3H-1 ceils have, in addition to a 
surface population of AChR, two discrete internal pools of AChR (57). Methods 
similar to those described by Patrick et al. (57) were used to quantitate these 
AChR receptor populations. Surface AChR was determined by binding [x2sI]c~- 
BuTx (10  -n M  for 60 rain) to cells and washing out unbound toxin as described 
above. Nonspecific [~2Sl]a-BuTx binding, defined as the binding that occurred in 
the presence of 2 X 10  -s M a-BuTx or 0.1 mM d-tubocurarine (dTc), was <  11~o. 
The labeled cells were harvested from the dish and centrifuged in a  table top 
clinical centrifuge for 10 rain at 1,000 rpm. The cell pellet was extracted for 3 h 
on ice in 0.2 ml NaC1/P~ containing 1% Triton X-100, I mM EDTA (1% NaCI/ 
Pi). After centrifugation of the extract at 1,000 rpm for 10 rain, aliquots of the 
labeled extract were  then  counted directly or after filtration through DEAE 
falters. To quantitate total internal AChR, cell surface receptors were first blocked 
with unlabeled c~-BuTx (10  -s M  for 60 rain) and excess toxin was removed by 
washing. Triton extracts were then prepared, 20/A was incubated with  10  -8 M 
[12~I]a-BuTx  for  30  rain  at  37°C,  and  the  amount  of complex  formed  was 
determined by DEAE  •ter  assay similar to  that  described by Schmidt and 
Raftery (61  ). The internal AChR is composed of two pools, a precursor to surface 
component and a hidden pool of unknown characteristics (57). The hidden pool 
was quantitated after cycloheximide depletion of the precursor to surface popu- 
lation from the total internal pool as in Patrick et al. (57). Following saturation 
of surface AChR with ct-BuTx, ceils were washed, harvested, and extracted as 
above. Quantitation of the AChR in the extracts was carried out by DEAE filter 
assay. The  size  of the  precursor to  surface component was calculated as the 
difference between the total internal pool and the hidden pool. Total cellular 
AChR was determined by DEAE filter assay of an untreated cell extract. 
In some cases, a spinning column toxin binding assay was employed. Samples 
of Triton extracts (400 pl) containing 3 ×  10  -9 M. [~2~l]a-BuTx were incubated at 
37°C for 90 rain. Bin-Gel P-30 columns were prepared in 3-ml syringes, equili- 
brated with 50 mM Tris C1, 0.1% Triton X-100, 1 mg/ml BSA, pH 7.4, and then 
centrifuged for 5  min at  1,000 rpm. The reaction mixture was appLied to the 
column and the spin was repeated. The fluid that passed through the columns 
was counted.  Lower molecular weight components such as unbound a-BuTx 
were retained by the column, whereas higher molecular weight material such as 
toxin-receptor complexes eluted in the void volume. Nonspecific binding (the 
binding that occurred after preincubation in the presence of saturating concen- 
trations of a-BuTx or 0.1 mM dTc) was subtracted. 
Subcellular Fractionation of BC3H-1 Ceils:  Cells were washed, 
harvested from the plates, and centrifuged in a clinical centrifuge as described 
above. The cell pellet was then suspended in 6 ml 1 mM triethanolamine, 0.25 M 
sucrose, pH 7.2 (tetraethylammohium [TEA] sucrose), and homogenized in a  17- 
ml zero clearance homogenizer for three strokes at 4°C using a  motor-driven 
pestle. The homogenate was then spun in a centrifuge (model JA 20; Beckman 
Instruments  Inc.) for  10 rain at  1700 g. The  supernatant was recovered and 
centrifuged at 33,000 g for 60 rain. The high speed pellet was resnspended in 1.0 
ml  TEA  sucrose  and applied  to  a  25%  vol/vol  Percoll  gradient which was 
prepared as follows: 2.5 ml 2.5 M sucrose was placed in the bottom of type 60 Ti 
centrifuge tube and was overlaid with 20 ml of a 25% vol/vol isoosmotic PercoU 
(d =  1.126 g/cm3)/TEA sucrose solution. The gradient was then centrifuged in 
a  type 60 Ti rotor for 20 rain at 45,000 g  with low acceleration, l-ml fractions 
were coLiected from the top. Densities were determined by the use of a density 
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In some experiments, the desired fractions were pooled and ehromatographed on 
a 0.7 x  75 cm Sephacryl S-1000 column. Fractions (1.5 ml) were collected and 
assayed for radioactivity and NA/3Gase. The appropriate fractions were pooled 
and concentrated by one of two methods. Pooled material was centrifuged over 
a  1.0-ml cushion of 2.5 M  sucrose for 60 rain at 33,000 g. The material at the 
interface was collected in a  minimal volume and diluted with  1.0 mM trietha- 
nolamine, pH 7.2, to the desired final sucrose concentration. Samples prepared 
in this manner were subsequently used for further fractionation purposes. Alter- 
natively, the sample was centrifuged over a  1.0-ml cushion of maxidens oil for 60 
rain at 33,000 g. The material at the interface was collected and made 1.0% in 
Triton X-100, and extracted on ice for 1 h. This material was used in subsequent 
velocity gradient sedimentation experiments. Samples intended for further sub- 
cellular fractionation studies were layered over 11.0 ml, 20--42% (wt/vol) metri- 
zamide gradients and centrifuged at 50,000 g for 18 h as described by Aas (1). l- 
ml fractions were collected from the top and analyzed for radioactivity, NA//Gase 
activity, and protein. The extracted samples to be analyzed by velocity gradient 
sedimentation were layered on 4.4 ml, 5-20% (wt/vol) sucrose gradients prepared 
in 1% NaCI/P~. The gradients were centrifuged at 102,000 g  for 20 h  in a  rotor 
(modal SW 56; Beckman Instruments, Inc.) and 180-p.1 fractions were collected 
by puncturing the  bottom of the tube. The fractions were then analyzed for 
radioactivity. 
RESU LTS 
Work from several laboratories has shown that the degradation 
rate of cell surface AChR can be measured by reacting them 
with [~25I]a-BuTx  and then monitoring the appearance in the 
culture  medium  of  ~2~I-monoiodotyrosine (12,  13,  57).  The 
turnover rate of the toxin-receptor complex is very similar to 
that of the unbound receptor (34, 52). In reasonable agreement 
with results from other laboratories, we found that AChR in 
BC3H- 1 cells are degraded with a haft-time of ~ 11-16 h (Figs. 
1 and 2). Radioactivity in the medium was identified as mon- 
oiodotyrosine by comparing its elution position on Bio-Gel P- 
2 with that of a  standard (data not shown). Treatment of the 
cells with the lysosomal protease inhibitor, leupeptin, inhibits 
AChR degradation in a dose-dependent manner (Fig. I). The 
t~/2  for degradation was increased two- to sixfold, depending 
on  the  concentration of leupeptin present.  The  half-time of 
degradation as well as the sensitivity to leupeptin varied some- 
what with the stock of cells used and the time after plating. 
It was important to determine whether this inhibition was 
reversible. For this purpose  a  turnover-recovery experiment 
(Fig.  2)  was  carded  out.  Surface  AChR  were  labeled with 
[~25I]a-BuTx  and incubated in medium containing 60 #M leu- 
peptin. Half of the cultures exposed to leupeptin were washed 
free  of inhibitor after  19-h  exposure and  were incubated  in 
control media. The  results show that cultures treated in this 
manner regain a  turnover rate similar to that of the control 
cultures within 20 h of the media change. 
In  addition to  AChR  on  the  cell surface,  there  exists an 
internal pool of receptor which can be measured after blocking 
cell surface AChR with unlabeled a-BuTx (57). Previous work 
has shown that the internal pool is composed of at least two 
components.  One  component  is a  precursor to  surface pool 
which is depletable from its internal location by cycloheximide 
treatment and presumably represents newly synthesized AChR 
in  transit  to  the  plasma membrane.  The  other  component, 
termed the hidden pool, appears to be at no time accessible to 
the external milieu and has no assigned function. Since cultures 
exposed to leupeptin contained more AChR than control ceils, 
it was  important to determine which population of receptor 
was augmented. After a  19-h incubation in the presence of 40 
~M leupeptin, the amount of internal AChR measured after 
depleting the surface precursor component was increased ap- 
proximately two-fold (Table I). Little effect on either surface 
or precursor to surface pools was found. This series of experi- 
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FIGURE  1  Leupeptin  inhibition  of BC3H-1 AChR turnover.  BC3H-1 
cells  were  labeled  with  [12Sl]a-BuTx,  washed  and  incubated  in 
control  culture  medium  (tl/2  =  11.1  h)  (O), or medium  containing 
10#M  leupeptin (tl/2  =  18.2 h)  (i-I), 20#M  leupeptin (t~/2 =  31.2 h) 
(A), or 40#M leupeptin  ( tl/2 =  59.1  h) (V). The radioactivity released 
into  the  media was measured  at the times  indicated,  and  the data 
were used to calculate the turnover rates. 
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Recovery of  AChR  turnover  from  leupeptin  inhibition.  FIGURE  2 
Cells  were  labeled  with  [1251](~-BuTx,  washed  and  incubated  in 
control  medium  (0) or medium  containing 60#M  leupeptin  (E:]) for 
the  entire  time  course  of  the  experiment.  Other  cells  (A)  were 
labeled and washed as above, incubated  in the presence of 60 #M 
leupeptin  for  18  I/2  h,  and  then  washed  free  of  inhibitor  and 
incubated  in control  medium  for the remainder of the time.  AChR 
degradation was measured as described  in Materials and Methods. ments demonstrates that an internally located pool with some 
of the  characteristics  of the  hidden  pool  is  augmented  by 
leupeptin treatment. 
Additional results indicate, however, that the leupeptin-aug- 
mented  pool  is  distinct  from  the  pre-existing  hidden  pool. 
Cultures were exposed to control or leupeptin-containing me- 
dia  (60  /~M), in  both  the  presence  and  absence  of excess, 
unlabeled  a-BuTx.  After depletion  of the  surface  precursor 
pool  by  cycloheximide  treatment,  the  amounts  of internal 
receptors were measured. Receptors that are derived from the 
cell surface during the exposure to unlabeled a-BuTx would be 
blocked and, therefore, silent in a soluble toxin binding assay. 
Table II shows that a 24-h incubation in the presence of 60 laM 
leupeptin causes a three-fold buildup in the internal AChR. In 
control cultures, the size of the hidden pool is unaffected by 
the presence of excess a-BuTx in the culture medium. This is 
in agreement with the results of Patrick et al. (57) and indicates 
that the hidden pool in control cells is not derived from the 
surface. In contrast, a-BuTx in the medium during leupeptin 
exposure reduces the amount of internal receptors capable of 
binding  [12sI]a-BuTx  after  Triton  solubilization  to  the  level 
observed in control cells. This result is consistent with the idea 
that leupeptin promotes the accumulation of AChR internal- 
ized from the muscle cell surface and that these  represent  a 
new population of AChR not previously described in BC3H-1 
cells. 
Subcellular fractionation studies were carried out to identify 
the organeile in which the leupeptin-augmented AChR reside. 
Cultures treated in four ways were analyzed. Cells were labeled 
with [x25I]a-BuTx and then maintained for 15 h in control or 
leupeptin-containing  medium  (prelabeled  cultures).  Alterna- 
tively, unlabeled  cells were incubated  for  15  h  in control or 
leupeptin-containing medium and then labeled for a short time 
with [x25I]a-BuTx (postlabeled cultures). In the latter case, only 
surface receptors should be labeled with [125I]a-BuTx since the 
TABLE  I 
Effect of Leupeptin on AChR Populations 
AChR*  Ratio 
(leupep- 
teupep-  tin/con- 
Population  Control  tin~:  trol) 
fmol 
Surface  160  179  1.1 
Total  internal  118  201  1,7 
Hidden  96  174  1.8 
Precursor to surface  22  27  1.2 
Total  283  377  1.3 
* Average of duplicate determinations  (2-11% variation in  range). 
~: Cells were exposed to 40~M leupeptin for 19 h. 
TABLE  II 
AChR in Leupeptin-augmented Pool Are Surface Derived 
AChR*¶  Ratio,(leu- 
peptin/ 
Treatment  Control  Leupeptin~  control) 
fmol 
--a-BuTx  279  845  3.0 
+a-BuTx§  268  261  1.0 
* Internal  AChR  pools  were  measured  after depletion  of  surface  precursor 
component by cycloheximide treatment. 
:l: Cells were exposed to 60/~M leupeptin for 24 h. 
§ Unlabeled toxin (2 x  10  -a M) was present  in the medium. 
¶ Average of duplicate determinations  {4-7% variation in range). 
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incubation  is  too  short  to  allow  detectable  internalization. 
Finally, the cells were harvested, homogenized, and analyzed 
by  Percoll  rate  zonal  gradient  centrifugation.  Cultures  that 
were prelabeled and treated with control media show a single 
peak of radioactivity near the top of the gradient (Fig.  3A). 
This  material  represents  plasma membrane  since it is  found 
also  in postlabeled  cells  (Fig.  3 C).  The  amounts  of plasma 
membrane  AChR in  the  latter  two cultures  are very nearly 
identical, substantiating the results from the pool quantitation 
experiments (Table I). 
Gradient profiles from prelabeled cultures treated with leu- 
peptin contain, in addition to the surface membrane AChR, a 
denser peak of radioactivity (Fig. 3 B). This material sediments 
reproducibly as a  peak in fractions  16-20 (1.07-1.13 g/cm3), 
which is coincident with the NaflGase activity, a marker en- 
zyme for lysosomes. The enzyme activity of the peak fractions 
was 70% latent as measured by its activity in the absence of 
Triton.  The  dense  material  does  not  arise  from  artifactual 
vesiculation  of specialized  regions  of the  plasma  membrane 
during  homogenization  since  it  is  not  found in  postlabeled, 
leupeptin-treated cultures. Thus, leupeptin inhibition of AChR 
turnover causes a build up of a population of AChR which co- 
migrates with the lysosomal component of these cells on Percoll 
gradients. 
Further purification of the lysosomal component from pre- 
labeled  leupeptin-treated  cultures has been carded out in an 
attempt to determine whether the leupeptin-augmented AChR 
reside  in  lysosomes or  in  some  other  cellular  compartment 
which co-migrates with lysosomes on Percoil gradients. Before 
additional  purification  techniques  could be  employed,  how- 
ever, it was necessary to remove the Percoll from the NAflGase- 
containing cellular material. Gel fdtration chromatography on 
Sephacryl S-1000 was used to separate the subceilular material 
from the Percoll. Percoll particles have a mean diameter of 35 
nm and therefore elute within the included volume while the 
cellular material  elutes  in the void volume measured  by the 
elution position of 795-nm-diam beads (arrow, Fig. 4A). Both 
the radioactivity and the NAflGase activity from the Percoll 
gradient dense material of prelabeled cultures treated for 16 h 
with  15-#M leupeptin elute in the void volume (300-400-nm- 
diam exclusion limit).  The peak fractions were pooled, concen- 
trated,  and  applied  to continuous  20-42%  metrizamide  gra- 
dients for further fractionation by equilibrium density gradient 
centrifugation. Profdes of the radioactivity, NAflGase activity, 
and protein distribution of this purification step are shown in 
Fig. 4 B. Radioactivity peaks and NAflGase activity, although 
rather  broad,  remain  coincident.  The  density  of the  peak 
fraction is  1.15 g/cm  3, which is in agreement with the values 
found by others for the density of lysosomes in this medium 
(1). Total purification of the lysosomal fraction was 10-17-fold, 
based on the relative specific activity of NAflGase. 
Separation of the plasma membrane AChR from those in 
the presumptive lysosomal compartment on Percoll gradients 
allowed a comparison of the biochemical characteristics of the 
two receptor populations in leupeptin-treated  cells.  The sedi- 
mentation behavior of the two populations on sucrose velocity 
gradients  containing  Triton  was  examined.  Following chro- 
matography on Sephacryl S-1000 columns, samples were con- 
centrated,  solubilized with Triton,  and  applied to 5-20% su- 
crose gradients.  Purified  Torpedo californica AChR, BC3H-I 
plasma membrane receptor samples, and leupeptin-augmented 
material were run in parallel (Fig. 5). As expected, virtually all 
of the  plasma  membrane  receptor  sediments  coincidentally 
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FIGURE  3  Subcellular fractionation of control and leupeptin-treated BC3H-1 cells on Percoll gradients. Subcellular fractionation 
was carried out as described in Materials and Methods. (A) Cells were incubated with [12sl]~-BuTx to label surface AChR, washed 
to  remove unbound  toxin, and  maintained for 18 h  in control  medium.  Fractions from  the  Percoll gradient were analyzed for 
radioactivity (cpm, O).  (B)  Cells were labeled with  [12Sl]~-BuTx,  washed, and maintained for 18 h in medium containing 120 #M 
leupeptin. Fractions from the Percoll gradient were analyzed for radioactivity (cpm, A), Na/~Gase activity (nanograms product per 
minute per microliter, O)  and protein concentration  (nanograms per microliter, O).  (C)  Cells were incubated in control medium 
(0) or medium containing 120/~M leupeptin  (O)  for 18 h, and then surface AChR were labeled with  [12Sl]o~-BuTx. Fractions from 
the Percoll gradients were analyzed for radioactivity (cpm). 
with the 9S form of Torpedo AChR. The results are identical 
with AChR solubilized from plasma membrane obtained by 
Percoll gradient centrifugation of homogenates of prelabeled 
control,  prelabeled  leupeptin-treated,  or  postlabeled  control 
cultures. The leupeptin-augmented AChR from the lysosomal 
fraction, however, has two forms. Approximately two-thirds of 
this material sediments in the 9S position, while the remainder 
sediments to the bottom of the centrifuge tube. This indicates 
that a very high molecular weight form of the BC3H-1 receptor 
exists  in  the  leupeptin-angmented  population.  The  plasma 
membrane  AChR samples tested contained either very little 
(~5-10%) or no high molecular weight form. In three separate 
experiments,  27-34% of the leupeptin-augmented  AChR was 
large molecular weight. 
Turnover of  mammalian AChR has been shown to be energy 
dependent in other systems (12).  In BC3H-1 cells,  5/LM car- 
bonylcyanide ra-chlorophenylhydrazone (CCCP) causes a 3.5- 
fold increase in the tl/2 for degradation of the receptor (data 
1320  THE  ~OORNAL Of  CELL BIOLOGY • VOLUME 96, 2983 °°° t  A t °,, 
oooo  t 
f  lit  ';  f  J  i   oo, 
02  ~oT4  ~  ~~ 
Number  of Column  Volumes Eluted 
12oo 
1,000 
:,,  80C 
.o  600 
n~ 
400 
200 
-  B 
I  // 
t 
006 
-10.05 
Jo.o~ 
~ -lo.0~ ~ 
-10.02 
-I0.01 
I 
2  4  6  8  10  12 
Froction Number  Pellet 
FIGURE 4  (A) Chromatography of subcellular material on Sephacryl 
S-1000.  A  sample derived from  prelabeled cu[tures that had been 
exposed to  15/tM  leupeptin  for  16  h  was fractionated  by  Percoll 
gradient centrifugation.  Fractions 15-19 containing the leupeptin- 
augmented material were pooled and applied to a Sephacryl S-1000 
column  (0.7  x  75 cm)  equilibrated  with  TEA  sucrose  buffer.  The 
column  was eluted with  the same buffer at a flow rate of 10 ml/ 
cm2/h.  Fractions (1.5  ml)  were analyzed for radioactivity (cpm, A) 
and Na/YGase activity (nanograms product per minute per microliter, 
O).  tn a separate experiment, [12sl]Percoll (O) was analyzed identi- 
cally. The void volume of the column  (arrow) was determined by 
the  elution  position  of  beads  with  a  diameter  of  795  nm.  (B) 
Purification  of  lysosomal fraction  on  a  metrizamide gradient. The 
dense peak of radioactivity from a Percoll gradient (fractions 15-19) 
of prelabeled, 15/~M leupeptin-treated cells was chromatographed 
on a Sephacryl 5-1000 column, concentrated, and fractionated on a 
continuous  20-42%  wt/wt  metrizamide  gradient  as  described  in 
Materials  and  Methods.  Fractions  were analyzed for  radioactivity 
(cpm, 0),  NaflGase activity (nanograms per minute per microliter, 
O), and protein concentration  (nanograms per microliter, A). 
not shown). The mechanism by which metabolic poisons cause 
the inhibition of AChR turnover may differ from the mecha- 
nism  of  inhibition  by  leupeptin.  Thus,  the  cellular  site  of 
accumulated  toxin-AChR  complexes may also differ.  There- 
fore, prelabeled cultures were treated with 2-deoxyglucose and 
CCCP for 15 h and then analyzed by subceilular fractionation 
(Fig.  6). No accumulation of label occurs in the dense region 
of the Percoll gradient where the lysosomal marker is known 
to sediment.  However,  the plasma  membrane peak of radio- 
activity of the treated cells is approximately twofold larger than 
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FIGURE  5  Comparison of AChR from plasma membrane and lyso- 
somal fraction by sucrose velocity gradient sedimentation. Fractions 
were  recovered  from  Percoll  gradients,  chromatographed  on 
Sephacryl S-I000 columns, concentrated, and solubilized with Triton 
X-100.  Samples  (200-p.l)  were  applied  to  5-20%  (wt/vol)  sucrose 
gradients and fractionated as described in Materials and Methods. 
Fractions were analyzed for radioactivity (cpm). (A) tysosomal frac- 
tion prepared from  prelabeled cells treated with  15/~M  leupeptin 
(O).  (B)  Plasma membrane fraction  from control,  prelabeled cells 
(O), prelabeled cells treated with  15 p,M  leupeptin  (Ill), or control, 
postlabeled ceils  (@). (C)  AChR standard  prepared by incubation 
of  affinity-purified  Torpedo  receptor  (0.26  Fg)  with  1  x  10  -8  M 
[1251]a-BuTx  for  60  min  followed  by  four-fold  dilution  with  1% 
NaCI/P~  (O). 
that of control ceils. Thus, in contrast to leupeptin treatment, 
the inhibition of AChR turnover by metabolic poisoning leads 
to an accumulation of receptor at the plasma membrane. 
We considered the possibility that the hidden pool of AChR 
may  reside  in  lysosomes,  even  though  it  is  apparently  not 
derived from the surface and its size is not affected by leupep- 
tin.  Cell cultures were treated such that only the hidden pool 
of AChR  would  be  detectable  in  a  solubilized  [1251]a-BuTx 
binding assay and then subjected to the subcellular fractiona- 
tion procedure. Fractions from a Percoll gradient were solubi- 
lized with Triton and tested for [125I]a-BuTx binding activity. 
Since the concentration of AChR in the Percoll gradient frac- 
tions was low, an alternative spinning column assay for binding 
was developed. As shown in Fig. 7, the majority of the receptor 
occurs  in  a  peak  that  is  well-resolved  from  the  NABGase 
activity.  The hidden pool component has a  density of 1.046- 
1.050 g/cm  3, whereas the NAflGase  activity shows a  charac- 
teristic  peak at a  density  of 1.079 g/cm 3.  The results  dearly 
demonstrate  that  the  hidden  pool  is  well-resolved  from  the 
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was carried  out  as described  in  Materials and  Methods.  Fractions 
from the Percoll gradient were analyzed for radioactivity (cpm). 
54,000 
48,000 
42D00 
~,, 56D00 
30,000 
~ 24,000 
m 
18,000 
12,000 
6,O00 
TOP  2  4  6  8  I0  12  14  16  18  20  22 
FraCtion Number 
i,s 
i.6 
1.4  r_; 
.= 
1.0  ~. 
0.8  ~ 
0.6 
0.4 
02 
FIGURE  7  Subceltular fractionation of hidden AChR pool on Percoll 
gradient. Cultures were treated with 50 p.g/ml cycloheximide for 3 
h to deplete the cells of the surface precursor pool and incubated 
with 2 x  10  -e M ~-BuTx for 1 h to block surfaceAChR. After washing 
away  unbound  a-BuTx,  cells  were  homogenized  and  subcellular 
fractionation was carried out by centrifugation on a Percoll gradient. 
Aliquots  of fractions  obtained were assayed for  NaflGase activity 
(nanograms per minute per microliter, @) and [1251]a-BuTx  binding 
activity (cpm, O) as described in Materials and Methods. 
lysosomal component but its sedimentation position does not 
indicate in which cellular organelle it resides. 
DISCUSSION 
Our measurement of the turnover rate for the AChR in the 
BC3H-1 system (t~/2 =  9-16 h) is in reasonable agreement with 
the value of 8 h  reported previously by Patrick et al. (57). In 
this system, we detected no degradative intermediates during 
the  course  of normal AChR  turnover,  possibly because  the 
rate-limiting step is endocytosis. For this reason, leupeptin was 
utilized in  an  attempt  to  accumulate  such  an  intermediate. 
Leupeptin treatment caused the inhibition of the turnover of 
surface AChR in a dose-dependent and reversible manner. An 
internal pool of receptor accumulated as a consequence of this 
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treatment, and this population was shown to be surface derived. 
Our results suggest that AChR in leupeptin-treated BC3H-1 
cells accumulates in lysosomes. The Percoll gradients used in 
this  study  afforded  a  clear  resolution of plasma membrane 
from lysosomes. The accumulated labeled material observed in 
leupeptin-treated, prelabeled cultures co-migrated with a  ly- 
sosomal enzyme  marker,  NABGase,  and  these  activities re- 
mained  coincident  throughout  two  additional  purification 
steps. The  possibility that the radio-labeled material is con- 
tained  in  a  contaminating  cellular compartmen  t  which  co- 
migrates with lysosomes is not excluded by these findings since 
lysosomes were not purified to homogeneity. In view of the 
coincident  behavior  of accumulated  AChR  and  NAflGase 
activity however,  it is reasonable to  assume  that  the  AChR 
accumulation in leupeptin-treated BC3H-1  cells occurs in the 
lysosome. Other laboratories have reported that leupeptin plus 
pepstatin inhibits AChR  degradation and  suggested on  this 
basis that receptor turnover proceeds via a lysosomal pathway 
(55). Our results showing accumulation of internalized AChR 
in a  compartment with lysosomal characteristics provide fur- 
ther support for this proposal. 
Libby et al. (46) reported a study of the effects of leupeptin 
and  other  inhibitors  on  AChR  turnover  in  cultured  chick 
muscle cells. In their system, leupeptin inhibited AChR deg- 
radation and caused the accumulation of an internal pool of 
receptors. The cellular compartment containing these AChR 
was sedimentable at 35,000 g. Ultrastructurat studies indicated 
that  leupeptin-treated cells  contained  three  times  as  many 
coated vesicles as control cells and, on this basis they suggested 
that the accumulated AChR  reside in coated vesicles. Using 
horseradish  peroxidase  conjugated-a-BuTx,  Bursztajn  and 
Fischbach (24) identified coated vesicles containing AChR in 
chick  muscle  ceils  treated  with  an  extract  of  chick  brain. 
However, only -20% of these coated vesicles became labeled 
in a l-6-h incubation of the myotubes with the toxin conjugate. 
Thus,  most of them are not derived from the surface. These 
results neither demonstrate nor discount a possible involvement 
of  coated vesicles in the AChR degradation pathway. Similarly, 
the evidence we present here does not rule out a coated vesicle 
step  in  the  turnover  process.  Untreated  chick myotubes are 
known to contain an internal pool of AChR derived from the 
cell  surface  (27).  This  permitted  an  autoradiographic study 
which demonstrated  that,  in  cells labeled with  [x25I]c~-BuTx, 
structures resembling secondary lysosomes contain radioactiv- 
ity (28). A  final resolution of the cellular location of internal- 
ized AChR in leupeptin-treated ceils as well as elucidation of 
the steps in the degradative pathway will require an autoradi- 
ographic study at the ultrastructural level. 
The possibility  that the radioactivity observed to accumulate 
due to leupeptin treatment does not represent internalized a- 
BuTx-AChR complexes but instead merely traces the path of 
dissociated or degraded toxin is excluded by the result obtained 
in the sucrose velocity gradient centrifugation studies. Two- 
thirds  of the  label  from  the  NAflGase coincident  material 
recovered from the PercoU gradients sedimented in a position 
near 9S,  the  characteristic sedimentation behavior of mono- 
meric Torpedo and mammalian AChR. It should be noted that 
in some cases the sedimentation patterns of intact and proteo- 
lyzed AChR  are very similar (51).  Thus,  this portion of the 
AChR from the lysosomal fraction is not necessarily unmodi- 
fied.  The  remainder  sedimented  as  a  very  high  molecular 
weight form which may be an important degradative interme- 
diate. In a  previously published report (44), the study of the 
degradation of proteins containing an amino acid analogue in the rabbit reticulocyte system revealed the formation of intra- 
cellular aggregates, one-third of which was sedimented by a 
10,000 g centrifugation. This high molecular weight form may 
be an analogous degradative intermediate to that portion of 
the  leupeptin-augmented,  NAflGase  coincident AChR  that 
behaves as an aggregate. Whether AChR aggregates actually 
exist in the cell or whether they represent modified receptors 
that are more prone to aggregation after Triton solubilization 
remains to be determined. Further studies will be required in 
order  to  examine  in  more  detail the  characteristics of this 
material. 
A hidden pool of AChR in BC3H-1 ceils has been described 
(57) as a portion of an internal pool which does not appear to 
function  as a  surface precursor  and  is not  accessible to  the 
external milieu at any time. This receptor population has no 
assigned  function,  nor  is  its  cellular location  known.  After 
solubilization, receptors from the hidden pool have a sedimen- 
tation coefficient 0.5--0.6S  lower than  surface receptors (57). 
Leupeptin inhibition of AChR turnover does not change the 
hidden  pool  size  but  rather  causes  an  accumulation  of  a 
receptor  subpopulation  that  is  surface  derived.  Subcellular 
fractionation  studies  demonstrated  a  further  distinction be- 
tween  the  hidden  and  leupeptin-augmented  pools.  A  clear 
resolution of the hidden pool from the NAflGase coincident, 
leupeptin-augmented AChR was obtained on Percoll gradients. 
The hidden pool of receptor migrated to a position that is less 
dense than the lysosomal peak and of greater density than the 
position of plasma membrane.  It is not  known  however,  in 
what  cellular  compartment  the  hidden  pool  resides.  More 
sensitive assays for other enzyme markers are needed in this 
system before this question can be answered. 
Morphological studies of internalized ct-BuTx-AChR com- 
plexes have provided most of the information concerning the 
pathway of AChR degradation. Electron microscopic autora- 
diographic studies of AChR  labeled with  [12sI]ct-BuTx  have 
shown that most receptors reside on the cell surface (45, 60), 
although some cytoplasmic staining has been observed as well. 
Intracellular AChR have been observed associated with Golgi 
apparatus  (6,  30),  lysosomes (28),  coated  vesicles (24),  and 
multivesicular bodies (6).  The  details of the  involvement of 
these intracellular compartments in AChR degradation remain 
to  be  elucidated.  The  biochemical  approach  that  we  have 
described here should be a useful complement to the morpho- 
logical studies.  In  particular,  it  should  now  be  possible to 
examine  the  effects  of other  inhibitors  that  may  block  the 
pathway at different steps. 
We thank our colleagues in the Department of Biochemistry for helpful 
discussions during the course of this work. 
This research was supported by U. S. Public Health Service grant 
NS 14871 and a grant from the Muscular Dystrophy Association. 
Received for publication 20 September 1982, and in revised  form  10 
January 1983. 
REFERENCES 
1.  Aas,  M.  1973. Separation  of mitochondria  and lysosomes from  rat  liver using a  new 
gradient  medium, "metrizamide".  lot. Congr.  Biochem. A bstr.  9:3 I. 
2.  Anderson,  D..L, and G. Blobel.  1981. In vitro synthesis, glycosylation, and membrane 
insertion  of the  four subunits  of Torpedo  acetylcholine receptor.  Proc.  NatL  Acad.  Sci. 
USA. 78:5598-5602. 
3.  Anderson, R. G. W., M. S. Brown, and J. L. Goldstein.  1977. Role oftbe coated endocytic 
vesicle in the uptake of receptor bound low density lipoprotein in human fibroblasts. Cell. 
10:351-364. 
4.  Anderson,  R.  G.  W.,  M.  S.  Brown,  U.  Beisiegei, and  J.  L.  Goldstein.  1982. Surface 
distribution and recycling of low density lipoprotein receptor as visualized with antirecep- 
tor antibodies. J. Cell Biol.  93:523-531. 
5.  Appel, S. H., R. Anwyl, M. W. McAdams, and S. Elias. 1977. Accelerated degradation of 
acetylcholine  receptor  from  cultured  rat  myotubes  with  Myasthenia  G-ravis sera  and 
globulins. Proc. Natl. A cad  Sei.  USA. 74:2130-2134. 
6.  Atsumi, S; 1981. Localization of surface and internal acetylcholine receptors by saponin 
treatment  of developing chick embryo muscle. Dee. BioL  86:122 135. 
7.  Baenziger,  .t.U.,  and  D.  Fiete.  1982. Recycling of the  hepatocyte  asialoglycoprotein 
receptor does not require delivery of ligand to lysosomes../. BioL  Chem. 257:6007-6009. 
8.  Baldwin, D., M. Prince, S. Marshall,  P. Davies, and J. M. Olfesky. 1980. Regulation  of 
insulin receptors: evidence for involvement of an endocytic internalization  pathway. Proc. 
NatL Acad.  Sci.  USA. 77:5975-5978. 
9.  Barazzone, P.,  M. A. Lesniak, P. Gordon,  E. Van Obberghen,  J.-L Carpentier,  and  L. 
Ocri.  1980. Binding,  internalization,  and  lysosomal association  of ~Z~l-human growth 
hormone in cultured human lymphocytes: a quantitative  morphological and biochemical 
study. J. Cell BioL  87:360-369. 
10.  Barret, A. J.  1972. Lysosomal enzymes. In  Lysosomes: A Laboratory  Handbook.  J. T. 
Dingle, editor, North-Holland  Publishing Co., Amsterdam.  17  18. 
11.  Banmarm, H., and D.  Doyle.  1980. Metabolic fate of cell surface glycoproteins during 
immunoglobulin induced internalization.  Cell 21:897-907. 
12.  Berg, D. K., and Z. W. Hall. 1974. Fate of aBungarotoxin  bound to acetylcholine receptor 
in normal and denervated muscle. Science (Wash. D. C).  184:473-475. 
13.  Berg, D. K., and Z. W. Hall.  1975. Loss of aBungarotoxin  from junctional  and extrajunc- 
tional  acetylcholine receptors  in rat diaphragm  muscle in  vivo  and  in organ  culture. J. 
Physiol. (Loud). 252:771-789. 
14.  Bevan, S., R. W. Kullberg, and S. F. Heinemann.  1977. Human  myasthenic sera reduce 
acctylcholine sensitivity of human muscle cells in tissue culture. Nature (Loud). 267:263- 
265. 
15.  Bralthewhite, A. W., and A. I. Hams. 1979. Neuronal influence on acetylcholine receptor 
clusters in embryonic development of skeletal muscles. Nature (Loud). 279:549 551. 
16.  Bridges, K., I. Harford, G. Ashwell, and R. D. Klausner.  I982. Fate of receptor and ligand 
during endocytosis of asialoglycoprotein by isolated hepatocytas.  Proc.  NatL  Acad.  ScL 
USA. 79:350-354. 
17.  Bradford, M. M.  1976. A rapid and sensitive method  for the quantitation  of microgram 
quantities of protein utilizing the principle of protein-dye binding. A naL  Biochem. 72:248- 
254. 
18.  Bramhall, S., N. Noack, M. Wu, and J. R. Lowenberg. 1969. A simple colorimetric method 
for the determination  of protein. Anal  Biochem.  31:146 148. 
19.  Brockes, J. P., and Z. W. Hall. 1975. Synthesis of acetylcholine receptor by denervated  rat 
diaphragm  muscle. Proc. NatL Acad  ScL  USA. 72:1368  1372. 
20.  Brockes, J. P., D. K. Berg, and Z. W. Hall. 1975. The biochemical properties and regulation 
of acetylcholine receptor in normal and denervated  muscle. Cold Spring  Harbor Syrup. 
Quant.  BioL  40:253-262. 
21.  Brown, M. S., and J. L. Goldstein. 1979. Receptor-mediated endocytosis: insights from the 
lipoprotein receptor system. Proc.  Natl. Acad  Sci.  USA. 76:3330-3337. 
22.  Burden,  S.  1977. Acetylcholine receptors at the  neuromuscular junction:  developmental 
change in receptor turnover. Dee. BioL 61:79-85. 
23.  Burden,  S.  1977. Development  of the  neuromuscular  junction  in the  chick  embryo: 
number, distribution, and stability of the acetylcholine receptor. De~. BioL  57:317-329. 
24.  Burszlajn, S., and G. D. Fischbach.  1980. Accumulation of coated vesicles bearing t~Butx 
binding sites in brai~ treated myotubes. Soc. Neurosci.  Abstr. 6:358. 
25.  Chang,  C.  C.,  and  M.  C.  Huang.  1975. Turnover  of junctional  and  extrajunctional 
acetylcholine receptors of the rat diaphragm.  Nature (Loud). 253:643-644. 
26.  Dennis,  M. J.  1981. Development  of the neuromuscular junction:  inductive interactions 
between cells. Annu.  Roy.  Neurosci.  4:43-69. 
27.  Devrentes,  P.  N.,  and  D.  M.  Fambrough.  1975. Acetylcholine  receptor  turnover  in 
membranes of developing muscle fibers. £  Cell BioL 65:335-358. 
28.  Devreotes, P.  N.,  and  D.  M. Fambrough.  1975. Turnover  of acetylcholine receptors  in 
skeletal muscle. Cold Spring  Harbor Syrup.  Quant.  BioL 40:237 251. 
29.  Drachman,  O. B. 1981. Biology of Myasthenia G ravis. A nnu.  Roy.  NeuroscL  4:195-225. 
30.  Fambrough,  D. M., and P. N. Devreotes. 1978. Newly synthesized acetylcholine receptors 
are located in the Golgi apparatus..L  Cell BioL  76:237-244. 
31.  Fambrough,  D.  M.  1979. Control  of acetylcholine receptors in skeletal muscle. PhysioL 
Rev. 59:165-227. 
32.  Fehlmann,  M., J.-L Carpentier,  A. LeCam, P. Thamm, D. Sannders, D. Brandenburg,  L. 
Orci, and  P.  Freychet.  1982. Biochemical and  morphological  evidence that  the insulin 
receptor is internalized with insulin in hepatocytes. Z  Cell BioL  93:82-87. 
33.  Froehner, S. C. 1981. Identification of exposed and buried determinants of the membrane- 
bound acetylcholine receptor from Torpedo californica.  Biochemistry.  20:4905-4915. 
34.  Gardner, J. M., and D. M. Fambrough.  1978. Properties of acetylcholine receptor turnover 
in cultured embryonic muscle cells. In Maturation of Neurotransrmssion. G. Filogamo, E. 
Giacobini,  and  A.  Vernadakis,  editors.  Karger  Int.  Soc. Neurochem.  Satellite  Syrup., 
Basel. 31~0. 
35.  Hall, Z. W., and C. G. Reiness. 1977. Electrical stimulation of denervated muscles reduces 
incorporation of methionine into ACh receptor. Nature (Loud.). 268:655-657. 
36.  Green,  A.,  and J.  M.  Olfesky.  1982. Evidence  for insulin-induced  internalization  and 
degradation of the insulin receptor in rat adipocytes. Proc. Natl. Acad.  Sci.  USA. 79:427- 
431. 
37.  Heinemarm,  S., S. Bevan, R. Kullberg,  J.  Lindstrom, and .L Rice.  1977. Modulation  of 
acetylcholine  receptor  by  antibody  against  the  receptor.  Proc.  Natl.  Acad.  ScL  USA. 
74:3090-3094. 
38.  Hizuka, N., P. Gorden, M. A., Lesniak, E. Van Obberghen, J.-L. Carpentier,  and L. Orci. 
1981. Polypeptide  hormone  degradation  and receptor  regulation  are coupled  to ligand 
internalization. J. Biol.  Chem. 256:4591-4597. 
39.  Huet, C.,J. F. Ash, and S. J. Singer. 1980. Theantibody-inducedclusteringandendocytosis 
of HLA antigens on cultured human flbroblasts. Cell. 21:429-438. 
40.  Hyman,  C., and S. C. Froehner.  1981. Acetylchnline receptor  turnover  in muscle cells: 
protease inhibition  causes accumulation  of internalized  receptors. J.  Cell Biol.  91 (2, Pt. 
2): 86a. (Abstr.) 
41.  Kalm, M. N., B. I. Posner, A. K. Verma, R. J. Kalm, and J. M. Bergeron. 1981. lntraceUular 
hormone  receptors:  evidence  for  insolin  and  lactogen  receptors  in  a  unique  vesicle 
sedimenting  in the lysosomal fractions of rat liver. Proc. NatL Acad.  Sci.  USA. 78:4980- 
4984. 
42.  Kalm, M. N., B. I. Posner, R. J. Kahn, and J. M. Bergeron. 1982. Internalization of insulin 
into rat liver  Golgi  elements. Evidence for vesicular heterogeneity and path of intracellular 
processing. Z  BioL  Chem. 257:5969-5976. 
43.  Kao, F., and D. B. Drachman.  1977. Myasthenic immunoglobulin accelerates acetylcholine 
receptor degradation  Science (Wash. DC).  196:527-529. 
44.  Klemes, Y., J.  D.  Etlinger, and A. L. Goldberg.  1981. Properties of abnormal  proteins 
HYMAN AND }:ROt:HNER  Effect of Leupeptin on ACh Receptor Degradation  1323 degraded rapidly in reticulocytes.  J. Biol.  Chem.  256:8436-8444. 
45.  Land,  B. R., T. R.  Podleski,  E.  E. Salpoter,  and  M. M. Salpeter.  1977. Acetylcholine 
receptor distribution  on  rnyotubes  in culture  correlated  to  acetylcholine  sensitivity.  J. 
Physiol.  (Lond.). 269:155-176. 
46.  Libby,  P.,  S.  Bursztajn,  and  A.  L. Goldberg.  1980. Degradation  of the acetyicholiae 
receptor in cultured  muscle cells: selective inhibitors  and the fate of undegraded receptors. 
Cell.  19:481-491. 
47.  Linden,  D. C., and D. M. Famhrough. 1978. Biosynthesis and degradation ofacetylcholine 
receptors  in rat skeletal  muscles. Effects of electrical  stimulation.  Neuroscienee.  4:527-538. 
48.  Lindstrora,  J. M., M. E. Seybold,  V. A. Lemaon, S. Whittingham, and D. P. Duane. 1976. 
Antibody to acetyleholine  receptor in Myasthenia Gravis. Neurology.  26:1054-1059. 
49.  Lindstrom,  J. 1979. Autoimmune response  to acetyleholine  receptors  in myasthenia gravis 
and its animal model.  Adv.  Immunol. 27:1-50. 
50.  Lindstrom,  J., and P. Dau.  1980. Biology of Myasthenia Gravis. Annu. Rev.  Pharmacol. 
Toxicol.  20:337-362. 
51.  Lindstrom,  J., W. Gullick,  B. Confi-Troncoul,  and M. Ellisman.  1980. Proteolytic  nicking 
of acetylcholine  receptor.  Biochemistry.  19:4791~1795. 
52.  Merlie,  1.  P.,  J.  P.  Changeny, and  F.  Gros.  1976. Acetylcholine  receptor  degradation 
measured by pulse chase labeling.  Nature (Loud.). 264:74-76. 
53.  Merlie,  J. P., J. G. Hurler,  and R. Sebbane.  1981. Acetylcholine  receptor  synthesis  from 
membrane polysomes.  J. Biol.  Chem.  256:6995-6999. 
54.  Merlie,  J. P., and R. Sebbane.  1981. Acetylcholine  receptor  subunits transit a precursor 
pool before acquiring aBungarotoxin binding activity. Z  Biol.  Chem.  256:3605-3608. 
55.  Merlie, J. P., S. Heinemaaa, and J. M. Lindstrorn.  1979. Acetylcholine  receptor degradation 
in adult  rat diaphragms in organ culture  and  the effect  of anti-acetylcboline  receptor 
antibodies..I.  Biol.  Chem. 254:6320-45327. 
56.  Patrick,  J., and P. W. Bermau. 1980. Metabolism of nicotinic  acetylcholine  receptor.  In 
The Cell Surface and Neuronal Function.  C. W. Cotrnan,  G. Poste,  and G. I. Nicolson, 
editors.  Elsevier/North Holland Biomedical  Press, Amsterdam. 157-190. 
57.  Patrick, L, J.  McMillan,  H. Wolfson,  and  J. C. O'Brien.  1977. Acetylcholine  receptor 
metabolism in a nonfnsing muscle cell line. £  Biol.  Chem.  252:2143-2153. 
58.  Posner,  B. I., B. A. Patel, M. N. Kahn, and J. J. M. Bergeron.  1982. Effects of chloroquine 
on internalization  of l~l-insulin  into subcellular  fractions  of rat liver.  Evidence for an 
effect of chloroquine  on Oolgi elements..L  Biol.  Chem.  257:5789-5799. 
59.  Reiness,  C. G., C. Weinberg, and Z. W. Hall.  1978. Antibody  to acetylcholine  receptor 
increases  degradation of junctinnal and ¢xtrajunctional  receptors  in adult muscle. Nature 
(Loud.). 274:68-70. 
60.  Salpeter,  M. M.,  S. S. Panton, K. Holley,  and T. R. Podleski.  1982. Brain extract causes 
acetylcholine  receptor  redistribution  which  mimicks some early  events at developing 
neuromuscular junctions.  J.  Cell. Biol. 93:417~125. 
61.  Sckmidt,  J.,  and  M.  A.  Raftery.  1973. A  simple  assay for  the  study  of solubilized 
acetylcholine  receptors.  Anal.  Bioehem.  52:349-354. 
62.  Weigel, P., and J. Oka. 1982. Endocytosis  and degradation mediated by the asialoglyco- 
protein receptor in isolated  rat hepatocytes.  J. Biol.  Chem.  257:1201-1207. 
1324  THe  jOURNAL  OF  CELL BIOLOGY  - VoLume  96, 1983 